Guided Excimer Laser Technology
Glaucoma
Afflicts 80 million people worldwide and will surpass 100 million
people by 2040.
Over 80% of patients have
open-angle Glaucoma.
In a healthy functioning eye, pressure is regulated by the outflow of Aqueous fluid through a tissue called the trabecular meshwork. Often with Glaucoma, the meshwork fails, resulting in elevated pressure which irreversibly damages the optic nerve.
Treatment Options
Glaucoma is a chronic progressive condition and is the most common cause of irreversible blindness worldwide. Primary open angle glaucoma (POAG) is defined by an open, normal appearing anterior chamber angle and elevated intraocular pressure (IOP), with no other underlying disease. With Glaucoma, the eye lacks the ability to regulate its own pressure properly, resulting in permanent vision loss.
Current treatments are not adequate in controlling the disease progression:
Expensive, never ending, have multiple side effects and require ongoing compliance: 70% are not used.
Medications
SLT
Effects are short-term and efficacy is unpredictable,
1/3 of treated patients do not respond.
Invasive Surgery
A last resort, eye altering and life-style limiting. Requires ongoing close monitoring and ongoing interval adjusting.
MIGS
Less invasive, less risky, enhances existing outflow channels, patient independent. A far better option, however limited use due to required goniolens.
Excimer Laser Trabeculostomy
Over a decade ago, we invented Excimer Laser Trabeculostomy (ELT), the first MIGS procedure, to reestablish normal outflow of Aqueous fluid from the eye. This micro-invasive surgery creates multiple laser channels through the trabecular meshwork using a cold laser system, which minimizes tissue scaring, enhances longevity and aids in bypassing the main area of resistance to aqueous outflow.
The Problem
Goniolens based ELT is difficult to perform and requires complex training that is not universally available. A goniolens based ELT does not allow the surgeon to see beyond the surface of the trabecular meshwork. Identifying the proper placement for the procedure can therefore become an issue, and even with proper placement it is difficult to discern if the procedure was successful, causing low MIGS adoption rates.5
Introducing GELT™
Using our patented intelligent guidance system, your ophthalmologist can now identify the best placement for the procedure. This state of the art system utilizes OCT imaging to see the surface and depth of the targeted tissue, which would otherwise be invisible. In real time, GELT enables and optimizes the precise creation of long-lasting outflow channels using the excimer laser.
Can be performed by all cataract surgeons and provides visibly
obvious, real-time results.
Better identifies procedure
placement, extending results consistently beyond 12 years.6
